Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane with Capecitabine and Radiation for Pancreatic Cancer
NCT02394535Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2015
- Primary completion
- Aug 2022
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose. Started Nov 2015; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02394535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394535.